Clinical trial
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
NCT00021021 · Ribozyome, Industry · Completed
Key facts
| NCT number | NCT00021021 |
|---|---|
| Title | RPI.4610 in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer |
| Lead sponsor | Ribozyome, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | anti-FLT-1 ribozyme |
| Start date | Sep 1, 2001 |
| Completion | Feb 1, 2004 |
| First posted | Feb 16, 2004 |
| Last update posted | Mar 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: